U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C16H19N3S
Molecular Weight 285.407
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ISOTHIPENDYL

SMILES

CC(CN1C2=CC=CC=C2SC3=CC=CN=C13)N(C)C

InChI

InChIKey=OQJBSDFFQWMKBQ-UHFFFAOYSA-N
InChI=1S/C16H19N3S/c1-12(18(2)3)11-19-13-7-4-5-8-14(13)20-15-9-6-10-17-16(15)19/h4-10,12H,11H2,1-3H3

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.drugs.com/international/isothipendyl.html | https://www.ncbi.nlm.nih.gov/pubmed/22677929 | https://www.ncbi.nlm.nih.gov/pubmed/13792589 | https://www.ncbi.nlm.nih.gov/pubmed/14157559

Isothipendyl is a first generation H1 antagonist (antihistamine) and anticholinergic used as an antipruritic. It is nowadays scarcely used in the first line relief of allergies due to the anticholinergic side effect of somnolence but does have some limited use through topical application in the relief of insect bites and related itching (pruritus).

Originator

Chemiewerk Homburg
5
Sources: Arzneimittel-Forschung, Volume 7, Pages 237-52, Journal, 1957

Approval Year

1957
118
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2849
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
Calmogel

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
1 % single, topical
Recommended
Dose: 1 %
Route: topical
Route: single
Dose: 1 %
Sources:
https://pubmed.ncbi.nlm.nih.gov/6138212
unhealthy, 41
Health Status: unhealthy
Age Group: 41
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/6138212
Disc. AE: Allergic contact dermatitis...
AEs leading to
discontinuation/dose reduction:
Allergic contact dermatitis
Sources:
https://pubmed.ncbi.nlm.nih.gov/6138212
72 mg multiple, oral
Studied dose
Dose: 72 mg
Route: oral
Route: multiple
Dose: 72 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/13792589
unhealthy
Health Status: unhealthy
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/13792589
Disc. AE: Weakness generalised...
AEs leading to
discontinuation/dose reduction:
Weakness generalised (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/13792589
AEs

AEs

AESignificanceDosePopulation
Allergic contact dermatitis Disc. AE
1 % single, topical
Recommended
Dose: 1 %
Route: topical
Route: single
Dose: 1 %
Sources:
https://pubmed.ncbi.nlm.nih.gov/6138212
unhealthy, 41
Health Status: unhealthy
Age Group: 41
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/6138212
Weakness generalised 1 patient
Disc. AE
72 mg multiple, oral
Studied dose
Dose: 72 mg
Route: oral
Route: multiple
Dose: 72 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/13792589
unhealthy
Health Status: unhealthy
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/13792589
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
DY556280
https://www.001chemical.com/chem/482-15-5
3B Scientific (Wuhan) Corp
3B2-1237
http://www.3bsc.com/index/pro_info.php?id=54953
AHH Chemical co.,ltd
MT-52993
http://www.ahhchemical.com/product/MT-52993.html
Alfa Chemistry
482-15-5
https://www.alfa-chemistry.com/isothipendyl-cas-482-15-5-item-292149.htm
Clearsynth
CS-T-56921
https://www.clearsynth.com/en/CST56921.html
eNovation Chemicals
D674442
https://www.enovationchem.com/ProductDetails.asp?ProductID=D674442
Finetech
FT-0670563
http://www.finetechnology-ind.com/prod/detail/pub/482-15-5.html
Molcore
MC556280
https://www.molcore.com/product/482-15-5
MuseChem
I007385
https://www.musechem.com/product/I007385.html
Smolecule
S530976
http://www.smolecule.com/products/s530976
THE BioTek
bt-270103
https://www.thebiotek.com/product/inhibitors/bt-270103
Yuhao Chemical
RT10332
http://www.chemyuhao.com/482-15-5.html
PubMed

PubMed

TitleDatePubMed
Bis[N,N-dimethyl-1-(10H-pyrido[3,2-b][1,4]benzothia-zin-10-yl)propan-2-aminium] tetrakis-(thio-cyanato-κN)cobaltate(II).
2010-06-16
Spectrophotometric studies on the investigation of chromium in environmental samples.
2003-01
Spectrophotometric determination of molybdenum(VI) using isothipendyl hydrochloride and pipazethate hydrochloride in alloy steels and soil samples.
2001-09
Phototoxic and photoprotective effects of topical isothipendyl.
1995-04
Patents

Patents

JPS62265225A
2

Sample Use Guides

In Vivo Use Guide
The dosage of isothipendyl in children was 6 to 8 mg. daily given as a syrup containing 2 mg. per teaspoonful. In adults the dosage varied from one 4 mg. tablet thrice daily to two 12 mg. sustained-action tablets thrice daily
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
ISOTHIPENDYL
INN   MI   WHO-DD  
INN  
Official Name English
ACTAPRONT
Preferred Name English
D-201
Code English
UDANTOL
Brand Name English
ODANTOL
Brand Name English
(±)-ISOTHIPENDYL
Common Name English
ISOTHIPENDYL [MI]
Common Name English
isothipendyl [INN]
Common Name English
DIMETHYLAMINOISOPROPYLAZAPHENOTHIAZINE
Systematic Name English
10H-PYRIDO(3,2-B)(1,4)BENZOTHIAZINE-10-ETHANAMINE, N,N,.ALPHA.-TRIMETHYL-
Systematic Name English
10-(2-DIMETHYLAMINOPROPYL)-10H-PYRIDO(3,2-B)(1,4)BENZOTHIAZINE
Systematic Name English
10H-PYRIDO(3,2-B)(1,4)BENZOTHIAZINE, 10-(2-(DIMETHYLAMINO)PROPYL)-
Systematic Name English
Isothipendyl [WHO-DD]
Common Name English
N-DIMETHYLAMINOISOPROPYLTHIOPHENYLPYRIDYLAMINE
Systematic Name English
AY-56012
Code English
Classification Tree Code System Code
WHO-ATC D04AA22
Created by admin on Mon Mar 31 19:20:14 GMT 2025 , Edited by admin on Mon Mar 31 19:20:14 GMT 2025
WHO-VATC QD04AA22
Created by admin on Mon Mar 31 19:20:14 GMT 2025 , Edited by admin on Mon Mar 31 19:20:14 GMT 2025
WHO-ATC R06AD09
Created by admin on Mon Mar 31 19:20:14 GMT 2025 , Edited by admin on Mon Mar 31 19:20:14 GMT 2025
WHO-VATC QR06AD09
Created by admin on Mon Mar 31 19:20:14 GMT 2025 , Edited by admin on Mon Mar 31 19:20:14 GMT 2025
Code System Code Type Description
PUBCHEM
3781
Created by admin on Mon Mar 31 19:20:14 GMT 2025 , Edited by admin on Mon Mar 31 19:20:14 GMT 2025
PRIMARY
ECHA (EC/EINECS)
207-578-5
Created by admin on Mon Mar 31 19:20:14 GMT 2025 , Edited by admin on Mon Mar 31 19:20:14 GMT 2025
PRIMARY
ChEMBL
CHEMBL2111066
Created by admin on Mon Mar 31 19:20:14 GMT 2025 , Edited by admin on Mon Mar 31 19:20:14 GMT 2025
PRIMARY
SMS_ID
100000082856
Created by admin on Mon Mar 31 19:20:14 GMT 2025 , Edited by admin on Mon Mar 31 19:20:14 GMT 2025
PRIMARY
NCI_THESAURUS
C170083
Created by admin on Mon Mar 31 19:20:14 GMT 2025 , Edited by admin on Mon Mar 31 19:20:14 GMT 2025
PRIMARY
RXCUI
28012
Created by admin on Mon Mar 31 19:20:14 GMT 2025 , Edited by admin on Mon Mar 31 19:20:14 GMT 2025
PRIMARY RxNorm
MESH
C008214
Created by admin on Mon Mar 31 19:20:14 GMT 2025 , Edited by admin on Mon Mar 31 19:20:14 GMT 2025
PRIMARY
WIKIPEDIA
Isothipendyl
Created by admin on Mon Mar 31 19:20:14 GMT 2025 , Edited by admin on Mon Mar 31 19:20:14 GMT 2025
PRIMARY
EPA CompTox
DTXSID5048267
Created by admin on Mon Mar 31 19:20:14 GMT 2025 , Edited by admin on Mon Mar 31 19:20:14 GMT 2025
PRIMARY
FDA UNII
WVZ7K9P0JY
Created by admin on Mon Mar 31 19:20:14 GMT 2025 , Edited by admin on Mon Mar 31 19:20:14 GMT 2025
PRIMARY
INN
689
Created by admin on Mon Mar 31 19:20:14 GMT 2025 , Edited by admin on Mon Mar 31 19:20:14 GMT 2025
PRIMARY
MERCK INDEX
m6543
Created by admin on Mon Mar 31 19:20:14 GMT 2025 , Edited by admin on Mon Mar 31 19:20:14 GMT 2025
PRIMARY Merck Index
CAS
482-15-5
Created by admin on Mon Mar 31 19:20:14 GMT 2025 , Edited by admin on Mon Mar 31 19:20:14 GMT 2025
PRIMARY
DRUG BANK
DB08802
Created by admin on Mon Mar 31 19:20:14 GMT 2025 , Edited by admin on Mon Mar 31 19:20:14 GMT 2025
PRIMARY
DRUG CENTRAL
1507
Created by admin on Mon Mar 31 19:20:14 GMT 2025 , Edited by admin on Mon Mar 31 19:20:14 GMT 2025
PRIMARY
EVMPD
SUB08339MIG
Created by admin on Mon Mar 31 19:20:14 GMT 2025 , Edited by admin on Mon Mar 31 19:20:14 GMT 2025
PRIMARY
ACTIVE MOIETY
Structure of ISOTHIPENDYL
SALT/SOLVATE (PARENT)
Structure of ISOTHIPENDYL HYDROCHLORIDE
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966